MO-VERNE-GLOBAL
15.11.2021 14:02:11 CET | Business Wire | Press release
Verne Global , provider of sustainable data center solutions for high intensity computing, recently acquired by Digital 9 Infrastructure plc (D9), today announced that it is expanding its 40-acre data center campus by a further 10MW of constructed power capacity. The expansion is backed by D9, the investment trust that focuses on sustainable digital infrastructure assets, which will fund the $50m development of new enterprise-class data center space.
Ideally located with access to abundant, low-cost renewable energy and a highly reliable national electrical grid, the Icelandic data center company continues to attract a range of enterprise customers as demand for high intensity compute sees sustained growth across industries. As more companies look to decarbonize their digital infrastructure by powering intensive applications such as artificial intelligence, mathematical modelling and predictive analytics with cleaner, greener energy, Verne Global is expanding now to meet contracted demand. The data center company’s best-in-class onsite technical and operations team will continue to use its specialized expertise to work around the clock to support and optimize the high density environments and workloads it houses.
“We’re seeing sector after sector looking to move into high performance analytics environments and it’s exciting to scale our campus again alongside new and existing customers to meet that need,” said Dominic Ward, CEO at Verne Global. “It’s great to also take this first step into the future as part of the D9 Infrastructure platform, and we are all eagerly looking forward to what comes next.”
“We are proud to support Verne Global and play a part in bringing its vision for the future into reality,” said Thor Johnsen, Head of Digital Infrastructure at Triple Point, D9’s investment manager. “Powered by Iceland’s abundant green power, Verne Global’s expanded data center will be even better placed to provide resilient digital infrastructure that offers a true reduction in carbon emissions for its customers alongside long-term economic and sustainable stability.”
As part of this expansion, Verne Global is partnering with Integra Mission Critical , the modular data center solutions provider, to optimize its delivery of sustainable high intensity compute at scale while fitting out the new data center space. Utilizing Integra’s solution-driven engineering expertise to implement modular data center infrastructure will allow Verne Global to increase sustainability measures in line with its core mission, while promoting scalability and safety, and decreasing cost.
“Verne Global’s facility has been built from the ground up for highly specialist data center services that are sustainable, scalable and bespoke,” said John Kolar, Principal at Integra Mission Critical. “These mutual principles make our companies a natural fit and we’re so excited to be teaming up and putting our decades of experience in solution-driven engineering to good use to provide a quality turnkey infrastructure solution for the new space.”
SC21 delegates can visit Verne Global at the Data Centers by Iceland stand (#1819) at SC21 in St Louis, MO, 15-19 November, 2021.
About Verne Global
Verne Global delivers data center solutions for high intensity computing, engineered for optimal high performance compute and built upon 100% renewable energy. Our clean grid and stable climate cuts costs and energy usage, and our expert team provides on-site, around-the-clock support to maximize performance and flexibility for customer workloads.
Founded in 2012, our Icelandic data center campus powers some of the world’s most innovative and demanding industries, including financial services, earth sciences, life sciences, engineering, scientific research and AI.
About Integra Mission Critical
Integra Mission Critical delivers modular mechanical, electrical and plumbing (MEP) solutions for the mission critical sector. With in-house manufacturing facilities throughout the United States, Europe, and Asia, Integra Mission Critical has a global reach with a local focus. Our solutions-driven engineering enables us to meet each customer’s specific needs across the globe, whether that be specialized cooling for a specific climate, or sustainable solutions for backup power generation.
Integra Mission Critical leverages innovative designs and an integrated approach and combines them with our relentless passion to mitigate risk, compress the schedule, reduce costs, and close the gap between capex and revenue generation.
Founded in 2014, with a focus on cooling solutions, Integra Mission Critical has since expanded into electrical solutions (2017), ranging from electrical skids to modular electrical rooms, to complete modular data centers. Our North America headquarters are in Dallas, Texas with our European headquarters in London, England.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005074/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom